Toripalimab Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma

NCT06492629 | Active Not Recruiting Phase 2

• 1 other identifier: PTCL-001
• Study Type: interventional
• Target: 43
• Locations: 1 country
• Sites: 1

Brief Summary

To evaluate the efficacy of Toripalimab combined with Chidamide in the treatment of relapsed/refractory peripheral T-cell lymphoma.

Conditions

PTCL

Outcome Measures

Primary Outcomes (1)

• Objective Response Rate (ORR)

  The primary efficacy endpoint will be assessed based on the Lugano 2014 criteria for Objective Response Rate (ORR), which includes both Complete Response (CR) and Partial Response (PR).

  24months

Secondary Outcomes (1)

• Overall Survival (OS)

  24months

Study Arms (1)

Toripalimab Combined With Chidamide group

EXPERIMENTAL

Toripalimab:Intravenous infusion, 240mg, administered once every 3 weeks. Chidamide:Take 30 mg (6 tablets) each time, and take the medication twice a week, with at least 3 days between doses

Drug: Toripalimab; Drug: chidamide

Interventions

Toripalimab DRUG

Intravenous infusion, 240mg, administered once every 3 weeks, until the subject has been treated for 2 years, disease progression occurs, intolerable toxic reactions are experienced, or treatment is discontinued for other reasons.

Toripalimab Combined With Chidamide group

chidamide DRUG

Take 30 mg (6 tablets) each time, and take the medication twice a week, with at least 3 days between doses (such as on Monday and Thursday, Tuesday and Friday, Wednesday and Saturday, etc.), to be taken 30 minutes after meals.

Toripalimab Combined With Chidamide group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 18 years or older, both males and females are eligible;
• Histologically confirmed peripheral T-cell lymphoma (PTCL) that has relapsed or is refractory after at least one line of systemic therapy. The definitions are as follows:
• Relapse: Patients who achieved a Complete Response (CR) in previous treatments and have new lesions at the original site or elsewhere; Refractory: Patients who did not achieve CR after adequate treatment. For nasal-type NK/T-cell lymphoma, previous treatments must have included a chemotherapy regimen containing asparaginase;
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2;
• Expected survival of at least 3 months;
• At least one measurable lesion in two dimensions, with the following criteria:
• For intra-nodular lesions: Longest diameter \>1.5 cm, shortest diameter \>1.0 cm; For extra-nodular lesions: Longest diameter \>1.0 cm;
• Adequate organ function as follows (no use of blood components or cytokines within 14 days before the first administration of the study drug): Hematology: Neutrophil count (NEUT) ≥ 1.5 × 10\^9/L, Platelet count (PLT) ≥ 75
• \^9/L, Hemoglobin (HGB) ≥ 90 g/L; Liver function: Total serum bilirubin (TBIL) ≤ 1.5 × Upper Limit of Normal (ULN); Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) ≤ 2.5 × ULN; if there is liver metastasis, TBIL ≤ 3 × ULN, ALT and AST ≤ 5 × ULN; Renal function: Serum creatinine (Cr) ≤ 1.5 × ULN; Thyroid function: Thyroid-stimulating hormone (TSH) within the normal range; if TSH is abnormal, Free Triiodothyronine (FT3) and Free Thyroxine (FT4) should be within the normal range or abnormal without clinical significance;
• Signed an informed consent form and is able to comply with the visits and procedures specified in the protocol.

You may not qualify if:

• Diagnosed with Adult T-cell Leukemia/Lymphoma (ATLL);
• Confirmed central nervous system (CNS) infiltration of lymphoma, including brain parenchymal invasion, meningeal involvement, or spinal cord compression;
• T-cell lymphoma primarily starting extranodally in the skin, such as: Mycosis Fungoides/Sezary Syndrome (MF/SS), primary cutaneous CD30-positive T-cell lymphoproliferative disorders, primary cutaneous δγT-cell lymphoma, primary cutaneous CD8-positive aggressive, epidermotropic cytotoxic T-cell lymphoma, primary cutaneous acral CD8-positive T-cell lymphoma, lymphomatoid papulosis, primary cutaneous CD4-positive small to medium T-cell lymphoproliferative disorders;
• Patients who have previously used PD-1 monoclonal antibodies/PD-L1 monoclonal antibodies or Chidamide;
• Patients with certain specific past medical histories, such as active autoimmune diseases, type 1 diabetes, thyroid hormone replacement required for hypothyroidism (except Hashimoto's thyroiditis), severe mental illness;
• Patients who require the use of immunosuppressants or systemic or absorbable local hormone therapy for immunosuppressive purposes (dose \>10mg/d prednisone or other equivalent efficacy hormones) within 14 days before the first administration or during the study;
• Patients who have received radiotherapy, chemotherapy, hormone therapy, surgery, targeted therapy, or systemic treatment with antibody drugs within 4 weeks before the first administration; those who have used monoclonal antibody conjugated with radioactive isotopes or cytotoxins within 10 weeks before the first administration; patients who have not recovered to ≤grade 1 toxicity from previous anti-tumor treatments (except for alopecia);
• Patients with uncontrolled hypertension (systolic blood pressure ≥180mmHg and/or diastolic blood pressure ≥100mmHg);
• Patients who have undergone autologous stem cell transplantation within 3 months before the first administration;
• Patients with a history of organ transplantation or allogeneic bone marrow transplantation;
• Patients who have received or plan to receive live attenuated vaccines within 4 weeks before the first administration or during the study;
• Patients with a history of allergy to macromolecular protein preparations or anti-PD-1 antibodies;
• Patients with a history of or concurrent other malignant tumors (except for skin basal cell carcinoma and cervical carcinoma in situ that have been cured for more than 3 years);
• Patients with uncontrollable or severe cardiovascular diseases, those who have had New York Heart Association (NYHA) class II or above congestive heart failure, unstable angina, myocardial infarction, and other cardiovascular diseases within 6 months before the first administration;
• HIV-positive patients, or those with active hepatitis (for hepatitis B: reference to hepatitis B five items and HBV-DNA, transaminases, etc., for hepatitis C: reference to HCV antibodies and HCV RNA);

Sponsors & Collaborators

• Cancer Institute and Hospital, Chinese Academy of Medical Sciences: lead

Study Sites (1)

Department of Medical Oncology

Beijing, Beijing Municipality, 100021, China

Location

MeSH Terms

Interventions

toripalimab; N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director

Study Record Dates

• First Submitted: July 1, 2024
• First Posted: July 9, 2024
• Study Start: April 3, 2024
• Primary Completion: December 31, 2025
• Study Completion: December 31, 2025
• Last Updated: July 9, 2024

Record last verified: 2024-07

Locations

CN (1)